Quintiles adds TMD to oncology portfolio
This article was originally published in Clinica
Executive Summary
Professional healthcare services company Quintiles Transnational has strengthened its oncology offering by purchasing Targeted Molecular Diagnostics (TMD), a laboratory specialising in tissue-based testing. The deal provides Quintiles (Research Triangle Park, North Carolina) with in-house pathology capabilities for tissue-based testing, which the firm describes as being “a critical component of the modern-day oncology drug development process”. According to Quintiles’ senior vice-president Tom Wollman, TMD also gives the company access to important biomarker expression analysis know-how. Westmont, Illinois-based TMD also supports clinical trials for both biotech and pharmaceutical companies around the world, and offers more than 100 biomarker assays. Financial terms of the acquisition were not revealed.